Lansoprazole
Product Images NDC 16590-891

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Lansoprazole (NDC 16590-891). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Stat Rx Usa Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (Lansoprazole Dr 15mg Label 890)

Lansoprazole D/R 15mg capsules, package of 30, labeled as generic for Prevacid and distributed by STAT Rx USA LLC. Each delayed-release capsule contains 15mg Lansoprazole. The packaging includes NDC 16590-890-30 and manufacturing information from Sandoz Inc. Princeton, NJ.*

FDA Label Image

Label Image (Lansoprazole Dr 30mg Label 891)

Lansoprazole D/R 30 mg capsule label from STAT Rx USA LLC, containing 30 capsules. The label indicates it is a generic for Prevacid with delayed-release lansoprazole, manufactured for Sandoz Inc. Includes NDC 16590-891-30 and storage instructions between 59-86 degrees F. Displays prescription-only warning and lot/sample info.*

FDA Label Image

Chemical Structure (Lansoprazole 01)

Chemical structure of lansoprazole showing the molecular framework including a benzimidazole ring, sulfoxide group, and pyridine ring with trifluoromethoxy substitution.*

FDA Label Image

Figure (Lansoprazole 02)

A line graph titled 'Mean Severity of Day Heartburn By Study Day For Evaluable Patients' showing severity ratings over approximately 60 days from start of treatment. The y-axis represents mean heartburn severity from 0 (none) to 3 (severe), and the x-axis shows days from the start of treatment. The graph compares placebo, lansoprazole 15 mg QD, and lansoprazole 30 mg QD, indicating lower mean severity for the lansoprazole groups compared to placebo over time.*

FDA Label Image

Figure (Lansoprazole 03)

A line graph showing mean severity of night heartburn over study days for evaluable patients given placebo, lansoprazole 15 mg QD, or lansoprazole 30 mg QD. The vertical axis grades severity from 0 (none) to 3 (severe), and the horizontal axis shows days from treatment start, highlighting changes in symptoms over approximately 60 days.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.